Compare HIHO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | INDP |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.4M |
| IPO Year | 1996 | N/A |
| Metric | HIHO | INDP |
|---|---|---|
| Price | $1.11 | $3.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 2.1M |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | ★ 10.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $1.65 |
| 52 Week High | $2.21 | $47.60 |
| Indicator | HIHO | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | N/A |
| Support Level | $1.14 | N/A |
| Resistance Level | $1.75 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.80 | 0.00 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.